>latest-news

Waters' New Rapid Screening-DSC Set To Transform Pharmaceutical Testing

Waters Corp. launches TA Instruments RS-DSC for efficient thermal stability testing in biopharma.

Breaking News

  • Jul 31, 2024

  • Mrudula Kulkarni

Waters' New Rapid Screening-DSC Set To Transform Pharmaceutical Testing

Waters Corp. has launched the TA Instruments Rapid Screening-Differential Scanning Calorimeter (TA Instruments RS-DSC) for biopharmaceutical developers worldwide. This advanced high-throughput DSC is engineered for accurate thermal stability testing of high-concentration biological formulations, particularly for antibody drugs and engineered proteins.

Jianqing Bennett, Waters Corporation Senior Vice President of the TA Instruments Division, remarked, “Demand is increasing for higher concentration injectable drugs, and biologic developers are looking for stability testing that is fast and efficient. Our new Rapid Screening-DSC meets these needs by providing a high-throughput alternative to existing capillary DSCs and a more reliable and accurate option to differential scanning fluorescence (DSF) technologies.”

According to the company, the TA Instruments RS-DSC provides a more convenient and accurate method for evaluating biological drug stability and quality. It utilizes disposable microfluidic chips (MFCs) with low sample volumes, allowing up to 24 measurements simultaneously. This innovation minimizes the need for sample dilution, reduces repetitive instrument cleaning, and lowers the risk of contamination. Unlike DSF methods, it avoids sensitivity issues, delivering precise data on high-concentration samples. The RS-DSC also includes automated software that offers fast, accurate, and comprehensive insights into a sample's thermodynamic properties.

 

Ad
Advertisement